Secondary lymphoid-tissue chemokine (SLC/CCL21) is a CC chemokine that is constitutively expressed in various lymphoid tissues and binds to chemokine receptor CCR7 on mature dendritic cells (DCs) and distinct T-and B-cell sub-populations. In vivo, CCL21 regulates the encounters between DC and T cells and thus is a key regulator of adaptive immune responses. We asked whether CCL21 is able to augment immunogenicity of a DNA-based vaccine against Her2/neu in a Balb/c mouse model with syngeneic Her2/neu þ tumor cells (D2F2/E2). Mice were vaccinated intramuscularly with plasmid DNA (pDNA) on day 1 and boosted on day 15; tumor challenge was performed subcutaneously on day 25. Coexpression of CCL21 and Her-2/neu resulted in induction of a TH1-polarized immune response and substantial improvement of the protective effect of the DNA vaccine. Coexpression of tumor antigen pDNA(Her2/neu) with both pDNA(GM-CSF) and pDNA(CCL21) as adjuvants led to further improvement of protection by the vaccine (70% tumor-free mice on day 35 vs 40% with either adjuvant alone vs 5-10% with tumor antigen alone). Our results show that CCL21 is a potent adjuvant for DNA vaccination, particularly in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF). Clinical use of a pDNA(Her2/neu/CCL21/GM-CSF) vaccine might be particularly promising in minimal residual Her2/neu þ breast cancer.
Introduction
Chemokines are key regulators of innate and adaptive immune responses. In particular CCR7-ligands secondary lymphoid-tissue chemokine (SLC/CCL21) and EpsteinBarr-virus-induced-molecule-1-ligand-chemokine (ELC/ CCL19) have an important role in regulating the encounter between dendritic cells (DCs) and T cells in regional lymph nodes. Both DC and distinct T-cell subsets such as naı¨ve and central memory T cells express the cognate receptor CCR7. CCL21 is constitutively expressed by cells distributed throughout the T-cell zones of lymph nodes, spleen and Peyer's patches. Only activated DC migrating from the periphery into regional lymph nodes express CCR7, whereas steady-state DC residing in peripheral tissues do not. 1 Migrating DC from CCL19-and CCL21-deficient mice do not have a fully mature phenotype. 2 Besides orchestrating migration of effector cells, it could recently be demonstrated that cell surface-bound CCL21 (and CCL19) capture and prime T cells for immunological synapse formation 3 and that they are able to promote the motility of T cells in the lymph node of mice in vivo. 4 All these data convincingly demonstrate that CCL21 (and CCL19) can be considered as important natural adjuvants for emerging primary and secondary immune responses. 2 Owing to its role as a key regulator of immune responses, CCL21 is an attractive candidate molecule to be used as an adjuvant for genetic immunization by plasmid DNA (pDNA). DNA vaccines encoding tumor antigens offer many advantages compared with peptide-based vaccines, in particular, with respect to clinical application: they (1) may present multiple major histocompatibility complex class-I-and major histocompatibility complex class-II-restricted epitopes, (2) are strongly immunogenic due to the presence of CpG sequences in plasmid vectors used for clinical application, (3) can be easily produced on large scale in good manufacturing practices quality for clinical administration and (4) can be used across human leukocyte antigen barriers as the gene product may most likely be processed and presented by antigen-presenting cells of each individual patient, thereby selecting suitable epitopes. Importantly, plasmid vectors are not afflicted with safety concerns such as viral vectors. 5 Clinical application of DNA vaccines in humans has been largely disappointing so far. The reasons are diverse, but are mostly related to topics such as dosing, tissue distribution, differences in Toll-like receptor expression patterns between mice and humans and possibly an impaired immune competence of patients with advanced cancers. 5, 6 Therefore, new experimental approaches aiming at an amplification of immune responses induced by DNA vaccines are warranted.
Her2/neu is an oncogene belonging to the Her familiy of receptor tyrosine kinases and is overexpressed in about 30% of patients with breast cancer. 7 As Her2/neu is expressed on the cell surface it can serve as a target for both humoral and cellular immunotherapy approaches in animal models and in patients. [8] [9] [10] [11] In this study, CCL21 was used as an adjuvant for DNA vaccination in a Balb/c mouse tumor model with syngeneic Her2/neu expressing tumors.
Materials and methods

Animals
Female 6-to 8-weeks-old BALB/c mice (H-2k d ) mice were purchased from Charles River (Sulzfeld, Germany) and housed in our animal facility (Max Delbru¨ck Center for Molecular Medicine (MDC), Berlin, Germany) under standard pathogen-free conditions. Experiments have been approved by local authorities (LAGeSo, Berlin, Germany) and performed according to the German animal protection law.
Cell lines
Mouse mammary tumor cell line D2F2 is derived from a spontaneous mouse mammary tumor, which arose in a BALB/c background from the hyperplastic alveolar nodule cell line D2. D2F2/E2 is transfected with the human Her-2/neu expression vector pCMV/E2 and the selectable pDNA pRSV/neo. The Her2/neu-expressing cell line D2F2/E2 was maintained in 800 mg ml À1 of G418 (Life Technologies, Karlsruhe, Germany). These cell lines were kindly provided by Dr Thomas Kammerto¨ns (AG Blankenstein, MDC). The human Her2/neu-overexpressing breast cancer cell line SK-BR3 was purchased from American Type Culture cell bank (ATCC, Wesel, Germany) and used for flow cytometric detection of Her2/neu antibodies in the serum of the animals. The cell line was maintained in RPMI medium (Lonza, Verviers, Belgium) supplemented with 10% fetal calf serum (Biochrom, Berlin, Germany), 2.5 mM 2-mecaptoethanol (Invitrogen, Darmstadt, Germany), 0.5 mM sodium pyruvate (Lonza), 2 mM L-glutamate (Lonza), 0.1 mM MEM nonessential amino acids (Lonza) and 100 U ml À1 penicillin/streptomycin (Lonza; complete medium, CM). The expression of Her-2/neu protein in SK-BR-3 cells was confirmed by fluorescence-activated cell sorting staining using Phycoerythrin-conjugated anti-human Her-2/neu antibodies (BD Pharmingen, Heidelberg, Germany). In the D2F2/E2 cells used in our experiments, the percentage of Her2/neu expression was always 495%.
Plasmids pVax was purchased from Invitrogen. pDNA (Her-2/neu) encoding human Her-2/neu and the plasmid pRJB-GM containing murine granulocyte-macrophage colonystimulating factor (GM-CSF) were kindly provided by Dr S Preise and Dr T Kammerto¨ns (AG Blankenstein, MDC). The Her2/neu plasmid vector pVax/E2A contains the E2A gene from pCMV/E2A, which was cloned into the expression vector pVax. E2A contains a lysine to alanine mutation in nucleotide sequence position 2257-2258, which corresponds to position 753 of the amino acid sequence. This alteration leads to elimination of tyrosine signaling in the Her2/neu protooncogene, which is an important issue under safety aspects for a potential clinical vaccine development. The plasmid pDNA (CCL21) consists of pcDNA3 encoding human CCL21 under the control of a cytomegalovirus promoter. The plasmids were amplified in Escherichia coli X1-blue strain (Agilent Technologies, Amsterdam, the Netherlands) and purified using the EndoFree Giga-Prep-Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions.
Immunization and tumor challenge protocol Mice were injected twice intramuscularly (i.m.) with 100 mg pDNA on days 1 and 15. Each experimental group consisted of 5-10 mice. Mice were injected with pDNA (Her2/neu) plus pDNA(CCL21), pDNA(Her2/neu) plus pDNA(GM-CSF), pDNA(Her2/neu) plus pDNA(CCL21) plus pDNA(GM-CSF), pDNA(Her2/neu), pDNA(CCL 21), pDNA(GM-CSF) or mock vector alone (Figure 1 ). After 10 days, each vaccinated mouse was challenged with 2 Â 10 5 D2F2/E2 tumor cells. The appearance and the growth of tumors in these mice were observed. Progressively growing masses 41 mm in diameter were regarded as tumors. Tumor diameters were measured 1-2 times weekly. Tumor volumes were calculated as follows: tumor volume ¼ 1/6pd 3 (where d is diameter).
Preparation of splenocytes
Spleens were aseptically removed and a single-cell suspension was generated in complete medium. Erythrocytes were lysed by using erythrocyte lysis buffer (EDTA þ NH 4 Cl þ Na 2 CO 3 ). Finally, splenocytes were washed twice in RPMI-1640 and subsequently used for immunological assays. CCL21 as an adjuvant for Her2/neu DNA vaccination T Nguyen-Hoai et al
ELISpot assays
For ELISpot assays splenocytes were seeded into 4-6 wells (10 6 splenocytes per well) on a g-interferon (g-IFN) or interleukin-4 ELISpot plate (ELISpot Kit, BD Pharmingen). Peptides were added at a concentration of 1 mg ml
À1
. Incubation was performed overnight and ELISpot plates were developed according to the manufacturer's instructions. Evaluation was performed by means of an AID ELISpot reader system (AID, Strassberg, Germany). Results were expressed as 'spots per 10 6 splenocytes'. The following Her2/neu peptides were used: (1) . All peptides were purchased from WITA GmbH, Berlin, Germany and had a purity of 495%. Blocking experiments with addition of anti-CD8-and anti-CD4 antibodies into the ELISpot assays were performed in order to confirm CD8 þ T cells as the main source of peptide-specific g-IFN release. Briefly, ELISpot plates containing splenocytes from the different groups of mice were incubated with anti-CD8 antibody (1 mg per 10 6 splenocytes, clone 2.43, BD Pharmingen), anti-CD4 antibody (1 mg per 10 6 splenocytes, clone GK1.5, BD Pharmingen) or with IgG control antibody (BD Pharmingen). Further evaluation of the ELISpot assay was performed as described above.
Detection of anti-Her2/neu antibodies Detection of antigen-specific antibodies in the serum of animals by means of flow cytometry offers the advantage of antibody detection even if the respective recombinant protein is not routinely available or if its production is very cost-intensive. The assay uses target cells, which express the cognate antigen in order to detect serum antibodies in a second step by anti-mouse antibodies using flow cytometry. 13 Sera were collected from mice and stored at À20 1C. Before performing the assay, sera were thawed and subsequently diluted in phosphate-buffered saline (PBS) at different ratios (1:30, 1:60 and 1:120). Sera were then incubated with 3-5 Â 10 5 SK-BR-3 cells for 30-60 min at 4 1C. After that time, cells were washed twice with PBS. Pellets were resuspended in PBS containing 50 ml biotinylated anti-mouse IgG, anti-mouse IgG2a, anti-mouse IgG1 or control antibody (dilution 1:50; Perkin-Elmer, Boston, MA). Cells were incubated for 30-60 min at 4 1C, washed twice with PBS and resuspended in PBS containing 50 ml of streptavidin-APC (BD Pharmingen; dilution 1:200). Cells were incubated for 15-30 min at 4 1C, washed with PBS and resuspended in FACS buffer (1Â PBS containing 0.5% bovine serum albumin, 2 mM EDTA, 0.05% NaN 3 ) for flow cytometric analysis. Relative quantification of antiHer2/neu total serum IgG or IgG isotypes was performed by comparing the mean channel fluorescence in different samples. Mean channel fluorescence reflects the binding of anti-Her2/neu antibodies to SK-BR3 cells and is therefore a suitable parameter to evaluate the induction of humoral anti-Her2/neu immune responses.
Statistical methods
For comparison of the means of three or more groups, analysis of variance was used together with PRISM software. Student's t-test was used to compare the means between two groups. P-values o0.05 were considered statistically significant.
Results
CCL21 enhances tumor protection by a Her2
/neu DNA vaccine and shows synergistic activity with GM-CSF CCL21 was studied as an adjuvant for DNA vaccination in comparison with GM-CSF, which is a well-established adjuvant for tumor vaccination. Mice were immunized i.m. by pDNA on days 1 and 15; tumor challenge with Her2/neu þ syngeneic D2F2/E2 tumor cells was performed on day 25. The percentage of tumor-free mice as well as tumor growth was monitored thereafter. Mice were immunized i.m. with pDNA(Her2/neu), pDNA (Her2/neu) plus pDNA(CCL21), pDNA(Her2/neu) plus pDNA(GM-CSF) or pDNA(Her2/neu) plus pDNA (CCL21) plus pDNA(GM-CSF). Control groups were injected i.m. with pDNA (CCL21), pDNA(GM-CSF) or mock vector (pVax) alone (Figure 1 ). To exclude that the amount of plasmid vector alone affects vaccine efficacy, previous experiments had shown that additional application of mock vector (pVax) alone did not improve tumor protection by the Her2/neu DNA vaccine (data not shown). In our tumor model pDNA (Her2/neu) alone was not able to convey significant protection from tumor growth as compared with control groups. On day 35 after tumor challenge, the percentage of tumor-free animals was 8% in the group immunized with pDNA(Her2/neu) as compared with 8-12% in the control groups (pDNA(CCL21), pDNA(GM-CSF), pVax). However, in the group immunized with pDNA(Her2/neu) plus pDNA(CCL21), 38% of animals had remained tumorfree by day 35. This compared fairly well with the protection provided by pDNA(Her2/neu) plus pDNA(GM-CSF), showing that CCL21 is a potent adjuvant (Figure 2 ). Most interestingly, combination of a pDNA(Her2/neu) with both pDNA(CCL21) and pDNA(GM-CSF) as adjuvants led to a significantly higher level of tumor protection (70% on day 35; Figure 2 ). Comparison of the tumor growth slopes in each group of vaccinated animals showed that coexpression of CCL21 led to significant retardation of tumor growth as compared with pDNA (Her2/neu) alone. The most pronounced suppression of tumor growth was observed in the group immunized with pDNA(Her2/neu) plus pDNA(CCL21) plus pDNA(GM-CSF). Application of pDNA(CCL21), pDNA(GM-CSF) or pVax alone did not significantly influence tumor growth, whereas mice injected with pDNA(Her2/neu) alone showed a moderate retardation of the tumor growth slope (Figure 3 ). CCL21 induces TH1 polarization of an anti-Her2/neu T-cell response In the same experimental setting, anti-Her2/neu T-cell responses were assessed in each group of animals 10 days after the second vaccination by g-IFN-and interleukin-4 ELISpot assays using splenocytes and a mixture of different Her2/neu peptides. pDNA(Her2/neu) alone was not able to induce significant peptide-specific responses as compared with the control groups, which had been immunized with pVax, pDNA(CCL21) or pDNA(GM-CSF) alone. In the group of mice immunized with pDNA(Her2/neu) plus pDNA(CCL21), significant Her2/neu-specific T-cell responses could be detected by g-IFN-ELISpot (Figure 4 ). T-cell responses in this group were significantly stronger than in the group immunized with pDNA(Her2/neu) plus pDNA(GM-CSF). However, the highest level of T-cell immune response was detected in the group, which had been immunized with pDNA (Her2/neu) plus pDNA(CCL21) plus pDNA(GM-CSF; Figure 4 ). T-cell responses were always directed against peptides from the extracellular domain of Her2/neu, whereas peptides derived from the intracellular domain were not immunogenic (Figure 4) . T cells showed a predominant TH1 cytokine profile with peptide-specific g-IFN release (Figure 4a ), whereas interleukin-4 ELISpots were always negative (Figure 4b) . In order to confirm CD8 þ T cells as a main source of peptide-specific g-IFN release, blocking experiments with anti-CD8 and anti-CD4 antibodies were performed. These blocking experiments clearly showed that immune responses detected by g-IFN ELISpot assays were indeed Her2/neu-specific CD8 þ T-cell responses, as they could be substantially suppressed by anti-CD8 antibodies but not by anti-CD4 antibodies or control antibodies (Figures 4c-e) .
Induction of humoral anti-Her2/neu immune responses by CCL21
After vaccination with pDNA(Her2/neu), pDNA(Her2/ neu) plus pDNA(CCL21), pDNA(Her2/neu) plus pDNA (GM-CSF), pDNA(CCL21), pDNA(GM-CSF) or pVax, total serum IgG antibodies recognizing Her2/neu were not substantially increased over background levels (Figure 5a ). Only in the group immunized with pDNA (Her2/neu) plus pDNA(CCL21) plus pDNA(GM-CSF), induction of a significant anti-Her2/neu antibody response could be observed (Figure 5a ). When analysis of humoral immunity was restricted to anti-Her2/neu antibodies of IgG2a isotype, significant responses could be detected both in the groups immunized with pDNA(Her2/ neu) plus pDNA(CCL21) and pDNA(Her2/neu) plus pDNA(CCL21) plus pDNA(GM-CSF), again suggesting that CCL21 is able to induce TH1 polarization of an emerging anti-Her2/neu immune response (Figure 5b On day 25, tumor challenge was performed with 2 Â 10 5 Her2/neu þ syngeneic D2F2/E2 tumor cells. Tumor growth was monitored thereafter. Coexpression of CCL21 was able to improve tumor protection of the immunized animals. Data are pooled from two independent experiments (n ¼ 13 for each group of mice). *Po0.05 as compared with pDNA(Her2/neu) and all control groups; **Po0.05 as compared with pDNA(Her2/neu) plus pDNA(CCL21); pDNA(Her2/neu) plus pDNA(GM-CSF) and all control groups.
CCL21 as an adjuvant for Her2/neu DNA vaccination T Nguyen-Hoai et al pDNA(GM-CSF) did not induce significant levels of IgG2a anti-Her2/neu antibodies (Figure 5b ). In contrast, none of the groups showed significant levels of IgG1 antiHer2/neu antibodies after vaccination, again underlining TH1 polarization of the immune response (Figure 5c ).
Discussion
DNA vaccination targeting tumor antigens is an attractive approach with regard to clinical application as DNA vaccines can be used in patients as a 'general' vaccine across human leukocyte antigen barriers. Despite encouraging results in animal tumor models, genetic immunization in humans has been disappointing so far. Most of the strategies being pursued in order to render DNA vaccines more effective are based upon coexpression of molecules, which generate a more immunogenic microenvironment at the vaccination site/in regional lymph nodes. These strategies include DNA fusion vaccines with tetanus toxoid or hepatitis B virus surface antigen 14 and combinations with activating cytokines or chemokines. [15] [16] [17] [18] [19] In our study with CCL21, a key regulator of DC-and T-cell migration and thus immune synapse formation was coexpressed with pDNA encoding CCL21 as an adjuvant for Her2/neu DNA vaccination T Nguyen-Hoai et al Her2/neu. DC migration into regional lymph nodes is CCR7 dependent and there is general agreement that CCL21 (and CCL19) have a central role in this process leading to adaptive immune responses. 20, 21 The Her2/neu mouse tumor model we used in our study is well established and has previously been used by other groups. [22] [23] [24] In our study, the i.m. vaccination schedule had only limited efficacy when pDNA(Her2/neu) was used alone. Therefore, our tumor model is particularly appropriate for the initial evaluation of adjuvants for genetic immunization, as high protection by the tumor antigen-encoding plasmid vaccine itself would possibly preclude judgement of the potency of the adjuvant under investigation.
Here, we clearly demonstrate that CCL21 enhances tumor protection by a Her2/neu DNA vaccine in tumor challenge experiments. This effect is mediated, at least in part, by induction of a TH1-polarized T-cell immune response against Her2/neu. Additional protection by CCL21 in tumor challenge experiments was in the same order of magnitude as with GM-CSF, which is a wellestablished adjuvant for tumor vaccination. 25, 26 However, CD8 þ T-cell responses against the Her2/neu epitopes used in our experiments were significantly higher with CCL21 as an adjuvant than with GM-CSF. As CCL21 and GM-CSF nevertheless conferred the same degree of tumor protection, it remains an open question whether this is because of the choice of epitopes used for in vitro assays, differences in CD4 þ T-cell activation or differences in the activation of non-T-effector cells. As induction of IgG2a anti-Her2/neu antibodies with CCL21 as an adjuvant was also superior to GM-CSF, it could be speculated that CCL21 elicits stronger CD4 þ T-cell help than GM-CSF. Interestingly, combination of both CCL21 and GM-CSF as adjuvants led to both increased tumor protection and a significant enhancement of humoral and T-cell anti-Her2/neu immune responses, so that synergistic activity of these adjuvants can be assumed.
Anti-Her2/neu T-cell responses were mainly directed against major histocompatibility complex class-I epitopes from the extracellular domain of Her2/neu, whereas the intracellular domain seemed to be less immunogenic. Whether this is due to real differences in immunogenicity within the Her2/neu protein or the choice of peptide epitopes for T-cell assays remains to be clarified. Besides induction of an anti-Her2/neu T-cell response, our results also show that CCL21 is able to amplify a humoral antiHer2/neu immune response. Although anti-Her2/neu total IgG was not significantly elevated over background levels after vaccination with pDNA(Her2/neu) plus pDNA(CCL21) or pDNA(GM-CSF), analysis of IgG isotypes revealed that coadministration of CCL21 elicited a significant IgG2a anti-Her2/neu immune response. Again, combination of both CCL21 and GM-CSF showed synergistic activity in inducing a IgG2a antiHer2/neu immune response. These results fit well into the pattern of T-cell immune responses observed in our ELISpot assays and might be explained by different levels of activation within the CD4 þ T-cell compartment, at least in our experimental setting, which is focussed on the induction of primary (short-term) immune responses.
Although the results of our study are clearcut concerning improved efficacy of the Her2/neu DNA vaccine when combined with CCL21, the mechanism(s) by which tumor protection is achieved remains largely elusive. This does not only include effector mechanisms involved in tumor rejection but also the exact site and mode of action of CCL21 as an adjuvant for Her2/neu DNA vaccination T Nguyen-Hoai et al CCL21 after in vivo expression in our tumor model. On one hand, we show evidence that Her2/neu-specific humoral and T-cell immunity has a major role, as tumor protection correlates with immune responses observed in vitro. However, this does not exclude further effector mechanisms being involved, particularly in as far as the innate immune system is concerned. It has recently been shown that CCR7-mediated signals may also have a role for migration of natural killer cells and neutrophils. 27, 28 Furthermore, it is largely unknown where the chemoattractant CCL21 mainly exerts its effects after i.m. administration: at the injection site or in afferent lymphatic vessels/secondary lymphatic tissue. Physiologically, in mice, CCL21 colocalizes with lymphatic endothelial cells and is induced upon inflammation. 29, 30 Furthermore, some authors suggest secretion of chemokines by activated DC, thereby, amplifying the gradient, which directs DC migration toward regional lymph nodes. 31, 32 The dissection of the exact mechanism by which CCL21 amplifies anti-Her2/neu immune responses in our tumor model was beyond the scope of this study, in particular, because biological effects are likely to be diverse and because the function of possible factors such as DC and T cells are interdependent, complicating functional analysis in vivo, even in knockout mice. Nevertheless, we postulate that adjuvant activity of CCL21 in our model is mainly mediated by upregulation of CCL21 expression at the injection site, in afferent lymphatic vessels and in regional lymph nodes, thereby amplifying attraction of mature DC and T cells into regional lymph nodes and increasing the chance of an encounter between these cells.
Our results are in line with previous reports showing anti-tumor effects accompanied by TH1 immune responses after administration of recombinant CCL21 by intratumoral injection or by injection into regional lymph nodes in mouse models of pulmonary adenocarcinoma. 33, 34 Furthermore, intratumoral injection of DC transduced with CCL21 also led to systemic TH1-polarized anti-tumor immunity. 35, 36 Qin et al. 37 have recently demonstrated in a mouse tumor model for prostate cancer that immunogenicity of a multiepitope DNA vaccine encoding prostate-tumor-associated antigens can be enhanced by a CCL21/prostate antigenfusion gene.
In conclusion, there is a strong rationale for further development of clinical DNA vaccines containing CCL21 as an adjuvant. After having provided 'proof of principle' for CCL21 in a transplantable Her2/neu mouse tumor model, we will extend our studies to a more timeconsuming Her2/neu transgenic mouse model, which is more likely to simulate the clinical situation in tumor patients with strong tumor antigen-specific tolerance. As a clinical perspective for the development of Her2/neu DNA vaccines, a clinical study in Her2/neu þ breast cancer patients with minimal residual disease would be most appropriate. As the past decade has shown that tumor vaccination is not effective in patients with large tumor burden, vaccine development should be focussed on minimal residual disease after surgery or successful systemic therapy. In these patients, there is clear clinical evidence that humoral and T-cell immunity may be of clinical relevance. [9] [10] [11] The evidence for an improved T-cell activation provided by our study might be particularly important in the light of the so far unsatisfactory clinical activity of the current generation of tumor vaccines.
